Joshua Delaney
PFD Report
All Responded
Ref: 2024-0189
All 1 response received
· Deadline: 3 Jun 2024
Sent To
Response Status
Responses
1 of 1
56-Day Deadline
3 Jun 2024
All responses received
About PFD responses
Organisations named in PFD reports must respond within 56 days explaining what actions they are taking.
Source: Courts and Tribunals Judiciary
Coroner’s Concerns
The evidence of the General Practitioner in this case was to the effect that prior to this death, neither he nor his colleagues were aware that Propranolol carried any significant risk of death through deliberate overdose. The evidence of the doctor in question was that because of this specific incident, there has been a change in their approach to prescribing of Propranolol at his GP surgery, with smaller quantities prescribed to patients who might be at risk of taking an overdose. Shortly after this incident (11 February 2020) there was, coincidentally, an article in the British Medical Journal in respect of Propranolol, (“Doctors and paramedics must be better prepared to deal with propranolol overdoses”). However, the doctor’s evidence in the inquest was that he did not believe that GPs generally were currently aware of the risk of Propranolol overdoses.
The evidence from the Consultant Psychiatrist from the Community Mental Health Team was that they would not usually prescribe Propranolol, and he also considered that GPs may not be aware of the overdose risk posed by the drug.
The inquest also heard from the toxicologist, who gave evidence that her anecdotal experience was that there had in recent years been a significant number of deaths caused by Propranolol overdoses.
In the circumstances, I am concerned that doctors in General Practice may not be aware of the risks of fatal overdose from Propranolol, and that in the absence of greater awareness by GPs, the prescription of quantities of Propranolol to those at risk may cause future deaths.
6. ACTION SHOULD BE TAKEN
In my opinion action should be taken to prevent future deaths and I believe you and your organisation have the power to take such action.
The evidence from the Consultant Psychiatrist from the Community Mental Health Team was that they would not usually prescribe Propranolol, and he also considered that GPs may not be aware of the overdose risk posed by the drug.
The inquest also heard from the toxicologist, who gave evidence that her anecdotal experience was that there had in recent years been a significant number of deaths caused by Propranolol overdoses.
In the circumstances, I am concerned that doctors in General Practice may not be aware of the risks of fatal overdose from Propranolol, and that in the absence of greater awareness by GPs, the prescription of quantities of Propranolol to those at risk may cause future deaths.
6. ACTION SHOULD BE TAKEN
In my opinion action should be taken to prevent future deaths and I believe you and your organisation have the power to take such action.
Responses
Response received
View full response
Dear Coroner, Re: Regulation 28 Report to Prevent Future Deaths – Joshua Arthur Stafford Delaney who died on 19 January 2020.
Thank you for your Report to Prevent Future Deaths (hereafter “Report”) dated 8 April 2024 concerning the death of Joshua Arthur Stafford Delaney on 19 January 2020. In advance of responding to the specific concerns raised in your Report, I would like to express my deep condolences to Joshua’s family and loved ones. NHS England are keen to assure the family and the Coroner that the concerns raised about Joshua’s care have been listened to and reflected upon.
I am grateful for the further time granted to respond to respond to your Report, and I apologise for any anguish this delay may have caused Joshua’s family or friends. I realise that responses to Coroner Reports can form part of the important process of family and friends coming to terms with what has happened to their loved ones and appreciate this will have been an incredibly difficult time for them.
Your Report raises the concern that doctors in General Practice may not be aware of the risks of fatal overdose from Propranolol, and that in the absence of greater awareness by GPs, the prescription of quantities of Propranolol to those at risk may cause future deaths.
The National Institute for Health and Care Excellence (NICE) guidance on generalised anxiety disorder and panic disorder in adults (published on 26 January 2011) does not recommend the use of Propranolol in anxiety and there is no recommendation in the British National Formulary (BNF), which provides key information for prescribers on the selection, prescribing, dispensing and administration of medicines, to use Propranolol for the treatment of anxiety in isolation. The BNF does however provide dose information for Propranolol for the treatment of anxiety symptoms such as palpitation, sweating and tremor, reflecting the licensed dose for these indications and including information on the risk of overdose from Propranolol. Under the ‘important safety information’ section, there is also reference to the Health Services Safety Investigations Body (HSSIB) patient safety investigation from February 2020, regarding the potential under-recognised risk of harm from the use of Propranolol.
My colleagues from NHS England’s National Patient Safety Team have been engaging with NICE to flag the circumstances of Joshua’s death and inviting them to strengthen their cautions around the use of Propranolol. National Medical Director NHS England Wellington House 133-155 Waterloo Road London SE1 8UG
05/08/2024
Following our review of this case, it has also been agreed that NHS England will issue communications to GPs to reiterate that NICE do not recommend Propranolol as a treatment option for anxiety, and emphasising the risks involved in its administration, and we will do so as soon as practicable. NHS England are also engaging with the Medicines & Healthcare Products Regulatory Agency (MHRA), who we understand are also considering some communications on this issue. NHS England are happy to update the Coroner in due course and once communications have been issued.
I would also like to provide further assurances on the national NHS England work taking place around the Reports to Prevent Future Deaths. All reports received are discussed by the Regulation 28 Working Group, comprising Regional Medical Directors, and other clinical and quality colleagues from across the regions. This ensures that key learnings and insights around events, such as the sad death of Joshua, are shared across the NHS at both a national and regional level and helps us to pay close attention to any emerging trends that may require further review and action.
Thank you for bringing these important patient safety issues to my attention and please do not hesitate to contact me should you need any further information.
Thank you for your Report to Prevent Future Deaths (hereafter “Report”) dated 8 April 2024 concerning the death of Joshua Arthur Stafford Delaney on 19 January 2020. In advance of responding to the specific concerns raised in your Report, I would like to express my deep condolences to Joshua’s family and loved ones. NHS England are keen to assure the family and the Coroner that the concerns raised about Joshua’s care have been listened to and reflected upon.
I am grateful for the further time granted to respond to respond to your Report, and I apologise for any anguish this delay may have caused Joshua’s family or friends. I realise that responses to Coroner Reports can form part of the important process of family and friends coming to terms with what has happened to their loved ones and appreciate this will have been an incredibly difficult time for them.
Your Report raises the concern that doctors in General Practice may not be aware of the risks of fatal overdose from Propranolol, and that in the absence of greater awareness by GPs, the prescription of quantities of Propranolol to those at risk may cause future deaths.
The National Institute for Health and Care Excellence (NICE) guidance on generalised anxiety disorder and panic disorder in adults (published on 26 January 2011) does not recommend the use of Propranolol in anxiety and there is no recommendation in the British National Formulary (BNF), which provides key information for prescribers on the selection, prescribing, dispensing and administration of medicines, to use Propranolol for the treatment of anxiety in isolation. The BNF does however provide dose information for Propranolol for the treatment of anxiety symptoms such as palpitation, sweating and tremor, reflecting the licensed dose for these indications and including information on the risk of overdose from Propranolol. Under the ‘important safety information’ section, there is also reference to the Health Services Safety Investigations Body (HSSIB) patient safety investigation from February 2020, regarding the potential under-recognised risk of harm from the use of Propranolol.
My colleagues from NHS England’s National Patient Safety Team have been engaging with NICE to flag the circumstances of Joshua’s death and inviting them to strengthen their cautions around the use of Propranolol. National Medical Director NHS England Wellington House 133-155 Waterloo Road London SE1 8UG
05/08/2024
Following our review of this case, it has also been agreed that NHS England will issue communications to GPs to reiterate that NICE do not recommend Propranolol as a treatment option for anxiety, and emphasising the risks involved in its administration, and we will do so as soon as practicable. NHS England are also engaging with the Medicines & Healthcare Products Regulatory Agency (MHRA), who we understand are also considering some communications on this issue. NHS England are happy to update the Coroner in due course and once communications have been issued.
I would also like to provide further assurances on the national NHS England work taking place around the Reports to Prevent Future Deaths. All reports received are discussed by the Regulation 28 Working Group, comprising Regional Medical Directors, and other clinical and quality colleagues from across the regions. This ensures that key learnings and insights around events, such as the sad death of Joshua, are shared across the NHS at both a national and regional level and helps us to pay close attention to any emerging trends that may require further review and action.
Thank you for bringing these important patient safety issues to my attention and please do not hesitate to contact me should you need any further information.
Report Sections
Investigation and Inquest
On 7 August 2020 an inquest was opened into the death of Joshua Arthur Stafford Delaney. The inquest was concluded on 28 March 2024.
The medical cause of death was Propranolol toxicity.
The jury’s conclusion at the inquest was a narrative conclusion, including a conclusion that the deceased took an overdose while conscious of what he was doing and that he intended to end his life, but that after the act he regretted his decision.
The medical cause of death was Propranolol toxicity.
The jury’s conclusion at the inquest was a narrative conclusion, including a conclusion that the deceased took an overdose while conscious of what he was doing and that he intended to end his life, but that after the act he regretted his decision.
Circumstances of the Death
The deceased, aged 19 at the time of his death, was a young man with a history of mental illness and suicidal ideation, and who had made previous suicide attempts.
During the year prior to the index events, he had been prescribed Mirtazapine for anxiety and to help with sleep. Following his discharge from the Community Mental Health Team, he attended his GP in October 2019, with symptoms of anxiety and physical symptoms including palpitations and tachycardia. He was prescribed Propranolol to be taken times a day for days, and given tablets for this purpose. He was given further prescriptions of tablets of Propranolol at the beginning of November 2019, and again on 4 January 2020. He had seen his GP in early December 2019, who had intended that the deceased move to taking Propranolol ‘as required’ in order to wean him off its use.
In the early hours of 19 January 2020, the deceased took a large overdose of Propranolol, estimated by the toxicologist to have been , and was found collapsed. Despite prolonged attempts at resuscitation by the paramedics and in hospital, he died on 19 January 2020.
During the year prior to the index events, he had been prescribed Mirtazapine for anxiety and to help with sleep. Following his discharge from the Community Mental Health Team, he attended his GP in October 2019, with symptoms of anxiety and physical symptoms including palpitations and tachycardia. He was prescribed Propranolol to be taken times a day for days, and given tablets for this purpose. He was given further prescriptions of tablets of Propranolol at the beginning of November 2019, and again on 4 January 2020. He had seen his GP in early December 2019, who had intended that the deceased move to taking Propranolol ‘as required’ in order to wean him off its use.
In the early hours of 19 January 2020, the deceased took a large overdose of Propranolol, estimated by the toxicologist to have been , and was found collapsed. Despite prolonged attempts at resuscitation by the paramedics and in hospital, he died on 19 January 2020.
Similar PFD Reports
Reports sharing organisations, categories, or themes with this PFD
Related Inquiry Recommendations
Public inquiry recommendations addressing similar themes
Data sourced from Courts and Tribunals Judiciary under the Open Government Licence.